SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Featured Reports
Apr 28, 2021
Mar 12, 2021

Press Releases

21 Oct
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR ™ platform with Genovis’ novel IgG protease, Xork, to unlock the full potential of transformative gene therapies and treat certain IgG-mediated autoimmune diseases - - This
20 Oct
Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit
WATERTOWN, Mass. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
13 Oct
Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress
WATERTOWN, Mass. , Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced it will be presenting
04 Oct
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
Selecta’s ImmTOR™ platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies WATERTOWN, Mass. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging